Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Zai Lab On Regulatory Reforms And Effective Partnering In China

Executive Summary

Zai Lab's VP and Head of Business Development Jonathan Wang tells Brain Yang how the China FDA's regulatory reforms make China attractive to international biotechs, and that therapeutic areas such as oncology and anti-infectives are to benefit, along with partnering in China.


Related Content

How China Regulatory Reforms Ring In International Biotechs' New Year
China Looms Large Seeking New Funding, Deals At J.P. Morgan
Zai Lab Soars On Nasdaq Debut


Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts